Catalyst PharmaceuticalCPRX
CPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Employees: 167
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
98% more call options, than puts
Call options by funds: $490K | Put options by funds: $248K
69% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 35
56% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 90
7% more capital invested
Capital invested by funds: $1.89B [Q3] → $2.04B (+$141M) [Q4]
6% more funds holding
Funds holding: 312 [Q3] → 332 (+20) [Q4]
1.47% more ownership
Funds ownership: 80.27% [Q3] → 81.74% (+1.47%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
32%
upside
Avg. target
$33
37%
upside
High target
$35
44%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Baird Joel Beatty 32% 1-year accuracy 12 / 37 met price target | 32%upside $32 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 44%upside $35 | Buy Reiterated | 28 Feb 2025 |
Stephens & Co. Sudan Loganathan 15% 1-year accuracy 4 / 27 met price target | 36%upside $33 | Overweight Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 6 articles about CPRX published over the past 30 days
Positive
Zacks Investment Research
16 hours ago
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
19 hours ago
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada.
Neutral
GlobeNewsWire
1 week ago
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
Neutral
GlobeNewsWire
3 weeks ago
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE would be the first and only treatment option indicated for patients diagnosed with DMD in Canada.
Negative
The Motley Fool
3 weeks ago
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared.
Positive
Zacks Investment Research
1 month ago
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Positive
Investors Business Daily
1 month ago
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.
Positive
FXEmpire
1 month ago
Strong Revenue, Drug Performance Lift Catalyst Shares
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Positive
Zacks Investment Research
1 month ago
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Seeking Alpha
1 month ago
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offering an attractive asymmetric trade payoff with a potential 40% upside, despite risks associated with acquisition-dependent revenue growth.
Charts implemented using Lightweight Charts™